Kevin Kip

Join Dr. Centor as he speaks with Kevin Kip, VP for Clinical Analytics at the University of Pittsburgh, and Anum Saeed, Assistant Professor of Cardiology at UPMC. They delve into the intriguing study comparing semaglutide and empagliflozin for type 2 diabetes, highlighting critical outcomes such as mortality and cardiovascular events. They break down complex topics like emulating clinical trials using electronic health records and discuss how demographic factors influence treatment adherence. Their insights pave the way for future diabetes treatment strategies.